Clinical Genomics - Our service

We provide an extensive repertoire of genomic testing across cutting edge technology, resulting in accurate profiling of solid tumours and haematological malignancies, directing novel treatment strategies, personalised to the patient.

NHS England has created a Genomic Medicine Service to prepare the NHS to harness the power of genomic technology and science to improve the health of our population. Testing is now being delivered through single national testing network of seven Genomic Laboratory Hubs (GLHs). As part of The North Thames Genomic Laboratory Hub (GLH) we deliver consolidated somatic testing for cancer, whilst Great Ormond Street Hospital offers specialist rare and inherited genetic testing. The collaboration is led by Great Ormond Street Hospital (GOSH) and includes laboratories at Barts Health, University College Hospital and the Royal Free Hospital, the Royal National Orthopaedic Hospital, Imperial College Hospital and The Royal Marsden. 

Working closely with experts in oncology at The Royal Marsden and across the North Thames Genomic Laboratory Hub, we can bring novel testing to patients sooner, directing treatment strategies personalised to the patient. Our innovative genomic practice has led to successful collaborations in new clinical trials, as well as successful partnerships with pharmaceutical companies, bringing novel testing to patients sooner. We have experience in delivering large national projects, such as 100,000 Genomes Project and programmes supported by Cancer Research UK and the Institute of Cancer Research, whilst leading in genomic profiling of cancer patients.

CMP research staff Simina, with blonde ponytail, and Bhila Sivakantan, with long dark hair, wearing blue lab coats with research equipment in laboratory

What is Clinical Genomics?

Clinical Genomics can identify genetic changes in individual cancers, by using a variety of molecular and cytogenetic techniques, that make tumours susceptible to targeted treatments and which can lead to improved and personalised treatment for patients.

Why choose RMH Clinical Genomic Service?

The Royal Marsden, together with The Institute of Cancer Research, is the largest comprehensive cancer centre in Europe. 

Situated in the state-of-the art Centre for Molecular Pathology and working closely with our translational research team means we are at the forefront of applying new technologies to cancer care and can rapidly translate novel genomic tests and technologies into the diagnostic setting. Our laboratories are UKAS accredited (United Kingdom Accreditation Service) providing valuable assurance that our services are technically competent, and our organisation has been assessed to an internationally recognised standard. 

Close interaction with world leading experts in basic and translational research, pathologists & oncologists, across the North Thames Genomic Laboratory Hub, offers a unique environment for cancer research and clinical care. 

How to refer?

For details on how to refer please contact us.

For further information on the services offered please see our Service Specification guide

DR LISA THOMPSON - HEAD OF COMMERCIAL DEVELOPMENT

Our leading edge technology helps us to accelerate our research from the laboratory into the clinic and enables us to offer a truly personalised approach for cancer patients everywhere.